Topical anti-inflammatory combination

ABSTRACT

Provided, among other things, is a method of treating or ameliorating an indication of non-mucosal topical tissue comprising periodically applying to such disease affected tissue a composition comprising: an effective amount of an appropriate composition of herbal bioactive comprising active(s) of one or more of  Sambucus nigra, Centella asiatica  or  Echinacea purpurea , and an effective amount of a quaternary ammonium surfactant.

This application is continuation of U.S. patent application Ser. No.13/055,081, filed 21 Feb. 2011, which is a national stage filing of PCTApplication PCT/US2009/050661 (published as WO2010/011541), filed 15Jul. 2009, which PCT application claims the priority of U.S. Prov.Application No. 61/082,613, filed 22 Jul. 2008.

The present invention relates to an anti-inflammatory topical treatmentthat is applied, for example, as a cream, ointment, foam, or via apatch, or via a composition-infused fabric, or the like.

Certain herbal extracts have been clinically shown to be effective intreating or ameliorating certain conditions of the mouth. Described inWO 02/094300 and U.S. Pat. No. 7,285,295 are a number of usefulcombinations of herbal extracts for treating or ameliorating diseases ofmucosa, and dosage forms for delivering the extracts to discrete regionsof the mouth. For example, such combinations, in the delivery formdescribed in U.S. Pat. No. 7,285,295, have achieved, in an 80 patienttrial, an average of 50% pain reduction in the first ½ hour. In the sametrial, average lesion reductions of 40% were achieved in 4 hours.

These types of herbal actives are not believed to have achievedsubstantial application as topical agents for treating topical lesionsor other indications having inflammatory aspects. Similarly, quaternaryammonium surfactants, such as particularly cetylpyridinium chloride,have been used widely in oral rinses as antimicrobials. Applicants,however, have found that an oral rinse comprising an effective amount ofappropriate herbal actives and an antimicrobially effective amount of aquaternary ammonium compound that is surface active is surprisinglyeffective in ameliorating gingivitis. The herbal actives without thequaternary ammonium compound are, in this format, marginally effectivein diminishing experimental gingivitis created by subjects failing tobrush for two or three weeks. Quaternary ammonium compound alone ismarginally effective. The two types of agents together, however, aremarkedly more effective than is just the quaternary ammonium component.Against the backdrop of the effectiveness of the herbal actives alone,the marked increase in effectiveness in ameliorating gingivitis is morethan additive. Given this result, Applicants conclude that other topicalindications, such as those implicating mixed inflammatory and microbialetiologies, can be treated with the combination.

Provided herein are topical treatments in various compositional formatsthat ameliorate topical indications.

SUMMARY OF THE INVENTION

Provided, among other things, is a method of treating or ameliorating anindication of non-mucosal topical tissue comprising periodicallyapplying to such disease affected tissue a composition comprising: aneffective amount of an appropriate composition of herbal bioactivecomprising active(s) of one or more of Sambucus nigra, Centella asiaticaor Echinacea purpurea, and an effective amount of a quaternary ammoniumsurfactant. For example, the quaternary ammonium surfactant can comprisea 1-alkylpyridinium salt, where alkyl is C8-C36 (such as acetylpyridinium salt). The composition can be applied, for example, as afilm, patch. The active(s) of one or more of Sambucus nigra, Centellaasiatica or Echinacea purpurea can, for example, comprise anantiinflammatory amount.

Further provided is a lotion, gel, cream, ointment or suppositorycomprising: an effective amount of appropriate composition of herbalbioactive comprising active(s) of one or more of Sambucus nigra,Centella asiatica or Echinacea purpurea; and an effective amount of aquaternary ammonium surfactant. The herbal bioactive can comprise, forexample, active(s) of Sambucus nigra comprises 20 to 100% by weight ofplant active solids in the composition. The herbal bioactive cancomprise, for example, active(s) of a second plant extract from 1 to 50%by weight of plant active solids in the composition.

Also provided is a method of treating or ameliorating acne; contact oratopic dermatitis; impetiginized eczema; nummular eczema; endogenouschronic infectious dermatitis; stasis dermatitis; pyoderma; nuchaleczema and chronic eczematoid otitis externa; acne urticata; localizedor disseminated neurodermatitis; lichen simplex chronicus; anogenitalpruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses;mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis,versicolor); monliasis; intertrigo; pseudomonas infections; ecthyma,candidiasis; herpes simplex lesions; dermatophytoses; staphylococcalinfections (e.g., staphylococcal scalded skin syndrome); proctitis;hidradenitis suppurativa; intertrigo; rhinisitis; sinusitis; scabies;cutaneous larva migrans (hookworm); tinea (ringworm); urinary tractinfections; or cutaneous penile lesions, comprising periodicallyapplying to such disease affected tissue a composition comprising: aneffective amount of an appropriate composition of herbal bioactivecomprising active(s) of one or more of Sambucus nigra, Centella asiaticaor Echinacea purpurea, and an effective amount of a quaternary ammoniumsurfactant.

Further provided, among other things, is a method of treating orameliorating a wound comprising periodically applying to the wound acomposition comprising: an effective amount of an appropriatecomposition of herbal bioactive comprising active(s) of one or more ofSambucus nigra, Centella asiatica or Echinacea purpurea, and aneffective amount of a quaternary ammonium surfactant.

DETAILED DESCRIPTION OF THE INVENTION

1. Herbal Bioactives

Appropriate herbal bioactive compositions for use in the device includeextract of Sambucus nigra (SN), and/or plant extracts of Allium sativum(AS), Calendula officinalis (CO), Camellia sinensis (CS), Centellaasiatica (CA, also known as Gotu Kola), Commiphora molmol (CM),Echinacea purpurea (EP), Gaultheria procumbens (GP), Hypericumperforatum (HP), Krameria triandra (KT), Ligusticum porterii-osha (LP),Matricaria recutita, Melissa officinalis, Salix alba, Thymus vulgaris,Uncaria tomentosa, Usnea barbata or Vaccinium myrtillus. The herbalbioactive compositions can include, for example, Sambucus nigra extractin an amount from one of the lower percentages (by weight) recited inthe next sentence to 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80,85, 90, 95, 96, 97, 98, 99 or 100%. These lower percentages are 10, 15,20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90 or 95%. If asecond or third herbal bioactive is present, it may be present, forexample in amount from one of the lower percentages to one of the higherpercentages recited in the following sentences. Lower percentages forthe second or third extracts can be, for example, 0.5, 1, 2, 5, 10 or20%. Higher percentages can be, for example, 1, 2, 5, 10, 20, 30, 40 or50%. These ranges, and any other ranges described in this application,can include or exclude one or both endpoints.

The herbal bioactive can be a herbal extract. The term “extract” is usedherein to include all of the many types of preparations containing aneffective amount of active ingredients. Thus, the extracts can beproduced by cold extraction techniques using a variety of differentextraction solvents including, but not limited to, water, fatty solvents(such as olive oil), and alcoholic solvents (e. g. 70% ethanol). Coldextraction techniques are typically applied to softer parts of the plantsuch as leaves and flowers, or in cases where the desired activecomponents of the plant are heat labile. Alternatively, hot extractiontechniques, where such solvents are heated to a temperature above roomtemperature, can be used with the precise value of said temperaturebeing dependent on factors such as the properties of the chosen solventand extraction efficacy. Hot extraction techniques are more commonlyapplied to the harder, tougher parts of the plant, such as bark, woodybranches and larger roots. In some cases, sequential extractions need tobe performed in more than one solvent, and at different temperatures.Standard procedures for producing plant extracts (including hotextraction, cold extraction and other techniques) are described in manypublications including“Medicinal plants: a field guide to the medicinalplants of the Land of Israel” (in Hebrew), author: N. Krispil, Har Gilo,Israel, 1986 and “Making plant medicine”, author: R. Cech, pub. byHorizon Herbs, 2000.

Exemplary herbal bioactive compositions by weight percentage include:

Plant Extract Composition: C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 SN 7080 90 70 80 90 AS 30 20 10 CO 30 20 10 CA 30 20 10 CM 30 20 10 C13 C14C15 C16 C17 C18 C19 C20 C21 C22 C23 C24 SN 70 70 70 70 70 70 70 70 70 7070 70 AS 20 20 20 20 20 CO 10 20 20 20 20 CA 10 10 20 20 20 CM 10 10 10EP 10 10 10 GP 10 10 10 C25 C26 C27 C28 C29 C30 C31 C32 C33 C34 C35 C36SN 80 80 80 80 80 80 80 80 80 80 80 80 AS 10 10 10 10 10 CO 10 10 10 1010 CA 10 10 10 10 10 CM 10 10 10 EP 10 10 10 GP 10 10 10 C37 C38 C39 C40C41 C42 C44 C45 C46 C47 C48 SN 90 90 90 90 90 90 90 90 90 90 90 AS 10  9 8  7  6  5  9  8  7  6  5 CO  1  2  3  4  5 CA  1  2  3  4  5 C49 C50C51 C52 C53 C54 C56 C57 C58 C59 C60 SN 90 90 90 90 90 90 90 90 90 90 90AS 10  9  8  7  6  5  9  8  7  6  5 CM  1  2  3  4  5 EP  1  2  3  4  5C61 C62 C63 C64 C65 C66 SN 90 90 90 90 90 90 AS 10  9  8  7  6  5 GP  1 2  3  4  5 C67 C68 C69 C70 C71 C72 C74 C75 C76 C77 C78 SN 90 90 90 9090 90 90 90 90 90 90 CO 10  9  8  7  6  5  9  8  7  6  5 CA  1  2  3  4 5 CM  1  2  3  4  5 C79 C80 C81 C82 C83 C84 C86 C87 C88 C89 C90 SN 9090 90 90 90 90 90 90 90 90 90 CM 10  9  8  7  6  5  9  8  7  6  5 EP  1 2  3  4  5 GP  1  2  3  4  5 C91 C92 C93 C94 C95 C96 C98 C99 C100 C101C102 SN 90 90 90 90 90 90 90 90 90 90 90 CA 10  9  8  7  6  5  9  8  7 6  5 CM  1  2  3  4  5 EP  1  2  3  4  5 C103 C104 C105 C106 C107 C108C110 C111 C112 C113 C114 SN 90 90 90 90 90 90 90 90 90 90 90 EP 10  9  8 7  6  5  9  8  7  6  5 GP  1  2  3  4  5 HP  1  2  3  4  5 C115 C116C117 C118 C119 C120 C122 C123 C124 C125 C126 SN 90 90 90 90 90 90 90 9090 90 90 EP 10  9  8  7  6  5  9  8  7  6  5 KT  1  2  3  4  5 LP  1  2 3  4  5

The above amounts provide exemplary useful amounts ±0.5% for amountsfrom 1-2%, ±0.5 or 1% for amounts from 3-5%, ±0.5, 1 or 2% for amountsfrom 6-10%, ±1, 2, 3, 4 or 5% for amounts from 70-90% (with theforegoing percentage ranges being of the total extract amount byweight).

In some embodiments, the solids from the herbal bioactive(s) typicallycontribute amounts to the compositions from one of the following lowerendpoints or from one of the following upper endpoints. The lowerendpoints are 0.01, 0.02, 0.05, 0.1, 0.2, 0.5, 1, 2, 3, 4 or 5, 10, 15,20, 25 or 30 weight percent. The upper endpoints are 0.05, 0.1, 0.2,0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40 or 45 weightpercent.

In some embodiments the herbal bioactive can be one or more flavonoids,isoflavonoids, tocopherols, polyphenols, or similar agents often foundin herbal extracts.

Flavonoids can include, for example, flavonols or flavonolols [such as,without limitation, a rutoside: rutin (quercitin 3-O-rutino-side),quercitrin (quercetin 3-O-rhamno-side), isoquercitrin (quercetin3-O-glucoside), diosmin (diosmetin 7.beta.-rutinoside), astragalin(kaempferol 3-O-glucoside), kaempferol 3-O-rutinoside, myricitrin (ormyricetin 3-O-rhamnoside), robinin (or kaempferol 3-O-robinoside7-rhamnoside), kaempferitrin (or kaempferol 3,7-O-dirhamnoside),nobiletin, tangeretin]. Or, flavonoids can include, for example,flavones [such as, without limitation, rhoifolin (or apigenin7-O-neohesperido-side), luteolin 7-O-glucoside, scutellarin (orscutellarein 5-O-glucoside), pectolinarin (or pectolinarigenin7-O-rutoside), galuteolin (or luteolin 5-O-glucoside), acaciin (oracacetin 7-O-rhamnoglucoside)]. Or, flavonoids can include, for example,flavanones [such as, without limitation, liquiritin (or liquiritin4′-O-glucoside), naringin (or naringenin 7-O-neohesperido-side),hesperidin (or hesperetin 7-O-rut-inoside), eriodictin (or eridictiol7-O-rhamnoside)].

Isoflavonoids can include, for example: formononetin 7-O-glucoside (orononin), afromosin 7-O-glucoside (or wistin), genistein (or genistein7-O-glucoside), daidzin, glycitin, genistein 6-O-malonylglucoside,daidzein 6-O-malonylglucoside, genistein 6-O-acetyl-glucoside, iridin(or irigenin 7-O-glucoside), irisolone, tectoridin (or tectorigenin7-O-glucoside) or shekanin.

If any one of these specific bioactive agents is included in thecomposition it can be used in an amount corresponding to the amountfound in one of the above-described extracts.

2. Antimicrobial Agents

Antimicrobial quaternary ammonium surfactants can include, for example,1-alkylpyridinium salts, where alkyl is C8-C36 (or C8-C20, or C10-C20),and wherein the carbon ring members can be substituted with up to twoC1-C7 alkyl groups. For example, the composition can includecetylpyridinium chloride.

In some embodiments, the quaternary ammonium compound(s) typicallycontribute amounts to the compositions from one of the following lowerendpoints or from one of the following upper endpoints. The lowerendpoints are 0.005, 0.01, 0.02, 0.03, 0.04 and 0.05 weight percent. Theupper endpoints are 5, 4, 3, 2, 1, 0.9, 0.8, 0.7, 0.6, 0.5, 0.25, 0.15,0.14, 0.13, 0.12, 0.11, 0.10, 0.09 and 0.08 weight percent.

Such quaternary amines are traditionally used for their antisepticaction against bacteria and other microorganisms. In the treatmentsdescribed herein, such antimicrobial activity may or may not be theprimary mode of action for a given indication. However, an antimicrobialamount is believed to provide a good stand-in for determining how muchcompound to formulate.

In some part, and in some embodiments, it is believed that thetherapeutic effect is due to the cleansing action of antimicrobialquaternary amines Or, in some part, and in some embodiments, it may bethat the unexpectedly greater activity seen is an enhancement of theanti-inflammatory action of the herbal components by the antimicrobialquaternary amine.

4. Exemplary Topical Indications

The compositions of the invention can be used for the relief ofdermatoses and similar topical indications that may be complicated byfungal, bacterial or parasitic colonization, or viral infection. Suchmicrobial infection, if present, can be causative or secondary to thedermatosis. For wounds (including abrasions and bed sores), thecompositions of the invention are believed to speed healing, and providewound cleansing. The anti-inflammatory properties of the compositionsare believed to be well suited for ameliorating pressure ulcers (bedsores).

Examples include acne; contact or atopic dermatitis; impetiginizedeczema; nummular eczema; endogenous chronic infectious dermatitis;stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitisexterna; acne urticata; localized or disseminated neurodermatitis;lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani);folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea(capitis, cruris, corporis, pedis, versicolor); monliasis; intertrigo;pseudomonas infections; ecthyma, candidiasis; herpes simplex lesions;dermatophytoses; staphylococcal infections (e.g., staphylococcal scaldedskin syndrome); proctitis; hidradenitis suppurativa; intertrigo;rhinisitis; sinusitis; scabies; cutaneous larva migrans (hookworm);tinea (ringworm); urinary tract infections; cutaneous penile lesions(such as balanitis zerotica obliterans, penile lichen planus, or thelike); and the like.

In ameliorating acne, the compositions may reduce the growth of bacteriain the follicle (e.g., Propionibacterium acnes or Staphylococcusepidermidis), or may act to keep skin pores clear, or may act to reduceinflammation. For the purposes of this specification, acne includes allknown types of acne. Types of acne include, for example, acne vulgaris,cystic acne, acne atrophica, bromide acne, chlorine acne, acneconglobata, acne cosmetica, acne detergicans, epidemic acne, acneestivalis, acne fulminans, halogen acne, acne indurata, iodide acne,acne keloid, acne mechanica, acne papulosa, pomade acne, premenstralacne, acne pustulosa, acne scorbutica, acne scrofulosorum, acneurticata, acne varioliformis, acne venenata, propionic acne, acneexcoriee, gram negative acne, steroid acne, nodulocystic acne and acnerosacea.

The treatments of the invention are applicable to all topical surfaces.In certain embodiments, the treatments are well suited for use on non-mucosal surfaces.

Without being bound by theory, Applicants note that microbes, evensymbiotic microbes, are thought to release microbial mediators ofinflammation or trigger the release of cytokine. Accordingly, byreducing this stress at an affected tissue, the antimicrobial componentof the compositions can have an ameliorative effect even when theindication in question does not have a strong microbial component.

5. Exemplary Formulation Formats

The compositions of the invention can be formulated in any of the manycompositions used in topical or mucosal treatments. For example, thecompositions can be formulated as baths or soaks, solutions, lotions,gels, creams, ointments, suppositories, dressings adapted to release thecompositions, instillation solutions, foams, or the like. In certainembodiments, the compositions are applied in reservoir or adhesivepatches, or in films (such as described in US2007/149902).

In certain embodiments, the combination is formulated in a lotion, gel,cream, ointment or suppository.

6. Other Dosage Forms

In certain embodiments, the composition is administered in conjunctionwith another administration form, such as a film, patch or mucoadhesivesolid dosage form. This solid dosage form can be applied before,concurrently, or after administration of the composition. The solidforms can help deliver medicament to more severely affected, or moremechanically accessible tissue, while the composition deliversmedicament elsewhere. The medicament in the solid form can be the sameor different from that of the compositions of the invention. However,herbal extracts and extract mixtures as described above are usefullyemployed. For example, the dosage forms described in WO 02/094300 andU.S. Pat. No. 7,285,295 can be employed. Or, the film described in thean application, filed Jun. 20, 2007, titled “Anti-InflammatoryDissolvable Film”, Ser. No. 11/765,587, can be employed.

In certain embodiments, the other dosage form is adapted for systemicadministration, such as by oral dosage form or by i.v. For example, theother dosage form may be a systemically administered antibiotic.

7. Antiinflamatory Agents

In certain embodiments, the composition further comprisinganti-inflammatory agent(s), such as steroidal or nonsteroidalanti-inflammatory agents. Steroidal anti-inflammatory agents, includebut are not limited to, corticosteroids such as hydrocortisone,hydroxyltriamcinolone, alpha-methyl dexamethasone,dexamethasone-phosphate, beclomethasone dipropionates, clobetasolvalerate, desonide, desoxymethasone, desoxycorticosterone acetate,dexamethasone, dichlorisone, diflorasone diacetate, diflucortolonevalerate, fluadrenolone, fluclorolone acetonide, fludrocortisone,flumethasone pivalate, fluosinolone acetonide, fluocinonide, flucortinebutylesters, fluocortolone, fluprednidene (fluprednylidene) acetate,flurandrenolone, halcinonide, hydrocortisone acetate, hydrocortisonebutyrate, methylprednisolone, triamcinolone acetonide, cortisone,cortodoxone, flucetonide, fludrocortisone, difluorosone diacetate,fluradrenolone, fludrocortisone, diflurosone diacetate, fluradrenoloneacetonide, medrysone, amcinafel, amcinafide, betamethasone and thebalance of its esters, chloroprednisone, chlorprednisone acetate,clocortelone, clescinolone, dichlorisone, diflurprednate, flucloronide,flunisolide, fluoromethalone, fluperolone, fluprednisolone,hydrocortisone valerate, hydrocortisone cyclopentylpropionate,hydrocortamate, meprednisone, paramethasone, prednisolone, prednisone,beclomethasone dipropionate, triamcinolone, and mixtures thereof.

Other anti-inflammatory agents useful in the compositions include thenonsteroidal anti-inflammatory agents. The variety of compoundsencompassed by this group are well-known to those skilled in the art.For detailed disclosure of the chemical structure, synthesis, sideeffects, etc. of non-steroidal anti-inflammatory agents, reference canbe had to standard texts, including Anti-inflammatory and Anti-RheumaticDrugs, K. D. Rainsford, Vol. I-III, CRC Press, Boca Raton, (1985), andAnti-inflammatory Agents, Chemistry and Pharmacology 1, R. A. Scherrer,et al., Academic Press, New York (1974).

Specific non-steroidal anti-inflammatory agents useful in thecomposition invention include, but are not limited to: 1) the oxicams,such as piroxicam, isoxicam, tenoxicam, sudoxicam, and CP-14,304; 2) thesalicylates, such as aspirin, disalcid, benorylate, trilisate, safapryn,solprin, diflunisal, and fendosal; 3) the acetic acid derivatives, suchas diclofenac, fenclofenac, indomethacin, sulindac, tolmetin, isoxepac,furofenac, tiopinac, zidometacin, acematacin, fentiazac, zomepirac,clindanac, oxepinac, felbinac, and ketorolac; 4) the fenamates, such asmefenamic, meclofenamic, flufenamic, niflumic, and tolfenamic acids; 5)the propionic acid derivatives, such as ibuprofen, naproxen,benoxaprofen, flurbiprofen, ketoprofen, fenoprofen, fenbufen,indopropfen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen,tioxaprofen, suprofen, alminoprofen, and tiaprofenic; 6) the pyrazoles,such as phenylbutazone, oxyphenbutazone, feprazone, azapropazone, andtrimethazone; and mixtures of the foregoing.

Mixtures of these steroid and/or non-steroidal anti-inflammatory agentscan be employed, as well as the pharmologically acceptable salts andesters of these agents. For example, etofenamate, a flufenamic acidderivative, is particularly useful for topical application.

8. Mucoadhesives

In certain embodiments polymer(s) are added to the compositions of atype, relative amount, and concentration that is mucoadhesive. The termmucoadhesive, as used herein, is a material that adheres to a mucosaltissue surface in-vivo and/or in-vitro. Such adhesion will adherentlylocalize the dosage form onto the mucus membrane and in certainembodiments requires the application of a force of at least about 50dynes/cm2 to separate the mucoadhesive material from the mucus membrane.Crosslinked polyacrylic acid-moiety-containing polymers and/orpolysaccharide gums (e.g. chitosan) can be used to achieve suchmucoadhesion.

9. Misc. Embodiments

The invention further encompasses, among other things, the followingnumbered embodiments:

Embodiment 1. A method of treating or ameliorating an indication ofnon-mucosal topical tissue comprising periodically applying to suchdisease affected tissue a composition comprising: an effective amount ofan appropriate composition of herbal bioactive comprising active(s) ofone or more of Sambucus nigra, Centella asiatica or Echinacea purpurea,and an effective amount of a quaternary ammonium surfactant.

Embodiment 2. The method of embodiment 1, wherein the quaternaryammonium surfactant comprises a 1-alkylpyridinium salt, where alkyl isC8-C36.

Embodiment 3. The method of embodiment 2, wherein the 1-alkylpyridiniumsalt is a cetylpyridinium salt.

Embodiment 4. The method of one of embodiments 1-3, further comprisingapplying to a portion of the tissue a film, patch or an adhesive solidformulation comprising appropriate composition of herbal bioactivecomprising active(s) of one or more of Sambucus nigra, Centella asiaticaor Echinacea purpurea.

Embodiment 5. The method of one of embodiments 1-4, wherein thecomposition forms a mucoadhesive coating on mucosal surfaces.

Embodiment 6. The method of one of embodiments 1-5, wherein theactive(s) of one or more of Sambucus nigra, Centella asiatica orEchinacea purpurea comprise an antiinflammatory amount.

Embodiment 7. A lotion, gel, cream, ointment or suppository comprising:an effective amount of appropriate composition of herbal bioactivecomprising active(s) of one or more of Sambucus nigra, Centella asiaticaor Echinacea purpurea; and an effective amount of a quaternary ammoniumsurfactant.

Embodiment 8. The composition of embodiment 7, wherein the quaternarysurfactant comprises a 1-alkylpyridinium salt, where alkyl is C8-C36.

Embodiment 9. The composition of embodiment 7, wherein the1-alkylpyridinium salt is a cetylpyridinium salt.

Embodiment 10. The composition of one of embodiments 7-9, wherein thecomposition further forms a mucoadhesive coating on mucosal surfaces.

Embodiment 11. The composition of one of embodiments 7-10, whereinherbal bioactive comprising active(s) of Sambucus nigra comprises 20 to100% by weight of plant active solids in the composition.

Embodiment 12. The composition of one of embodiments 11, whereinactive(s) of a second plant extract from 1 to 50% by weight of plantactive solids in the composition.

Embodiment 13. A method of treating or ameliorating acne; contact oratopic dermatitis; impetiginized eczema; nummular eczema; endogenouschronic infectious dermatitis; stasis dermatitis; pyoderma; nuchaleczema and chronic eczematoid otitis externa; acne urticata; localizedor disseminated neurodermatitis; lichen simplex chronicus; anogenitalpruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses;mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis,versicolor); monliasis; intertrigo; pseudomonas infections; ecthyma,candidiasis; herpes simplex lesions; dermatophytoses; staphylococcalinfections (e.g., staphylococcal scalded skin syndrome); proctitis;hidradenitis suppurativa; intertrigo; rhinisitis; sinusitis; scabies;cutaneous larva migrans (hookworm); tinea (ringworm); urinary tractinfections; or cutaneous penile lesions, comprising periodicallyapplying to such disease affected tissue a composition comprising: aneffective amount of an appropriate composition of herbal bioactivecomprising active(s) of one or more of Sambucus nigra, Centella asiaticaor Echinacea purpurea, and an effective amount of a quaternary ammoniumsurfactant.

Embodiment 14. The method of embodiment 13, wherein the quaternaryammonium surfactant comprises a 1-alkylpyridinium salt, where alkyl isC8-C36.

Embodiment 15. The method of embodiment 14, wherein the1-alkylpyridinium salt is a cetylpyridinium salt.

Embodiment 16. The method of one of embodiments 13-15, furthercomprising applying to a portion of the tissue a film, patch or anadhesive solid formulation comprising appropriate composition of herbalbioactive comprising active(s) of one or more of Sambucus nigra,Centella asiatica or Echinacea purpurea.

Embodiment 17. The method of one of embodiments 13-16, wherein thecomposition forms a mucoadhesive coating on mucosal surfaces.

Embodiment 18. The method of one of embodiments 13-17, wherein theactive(s) of one or more of Sambucus nigra, Centella asiatica orEchinacea purpurea comprise an antiinflammatory amount.

Embodiment 19. A method of treating or ameliorating a wound comprisingperiodically applying to the wound a composition comprising: aneffective amount of an appropriate composition of herbal bioactivecomprising active(s) of one or more of Sambucus nigra, Centella asiaticaor Echinacea purpurea, and an effective amount of a quaternary ammoniumsurfactant.

Embodiment 20. The method of embodiment 19, wherein the quaternaryammonium surfactant comprises a 1-alkylpyridinium salt, where alkyl isC8-C36.

Embodiment 21. The method of one of embodiments 20, wherein the1-alkylpyridinium salt is a cetylpyridinium salt.

Embodiment 22. The method of embodiment 19, further comprising applyingto a portion of the tissue a film, patch or an adhesive solidformulation comprising appropriate composition of herbal bioactivecomprising active(s) of one or more of Sambucus nigra, Centella asiaticaor Echinacea purpurea.

Embodiment 23. The method of one of embodiments 19-22, wherein thecomposition forms a mucoadhesive coating on mucosal surfaces.

Embodiment 24. The method of one of embodiments 19-23, wherein theactive(s) of one or more of Sambucus nigra, Centella asiatica orEchinacea purpurea comprise an antiinflammatory amount.

Definitions

The following terms shall have, for the purposes of this application,the respective meanings set forth below.

-   -   effective amount

To treat the indications of the invention, an effective amount of apharmaceutical compound will be recognized by clinicians but includes anamount effective to treat, reduce, alleviate, ameliorate, eliminate orprevent one or more symptoms of the disease sought to be treated or thecondition sought to be avoided or treated, or to otherwise produce aclinically recognizable favorable change in the pathology of the diseaseor condition. Thus, an effective amount can be, for example, an amountthat reduces the severity or duration of oral lesions, ulcerations,bleeding, irritation, swelling, erythema, or the like. For the presentcombination, it will be recognized that an effective amount is an amountthat, in the combination, is effective. By way of example, if componentA at concentration A1 is ineffective, component B is effective atconcentration B1, and concentrations A1+B1 are more effective, then A1is an effective amount in the combination. Or, for example if A1 and B1are ineffective, but A1+B1 are effective, then A1 and B1 are effectiveamounts in the combination.

-   -   microbial infections

Microbial infections include, without limitation, bacterial,mycobacterial, fungal and viral infections.

-   -   topical

“Topical” means the any topical surface of a subject (e.g., patient),such as skin (including under the scalp), nasal, sinus, vaginal, penile,urinary or anal surfaces.

-   -   treatment

“Treatment” means the management and care of a patient for the purposeof combating a disease, disorder or condition. The term is intended toinclude the delaying of the progression of the disease, disorder orcondition, the alleviation, amelioration or relief of symptoms andcomplications, and/or the cure or elimination of the disease, disorderor condition. The animal to be treated can be a mammal, in particular ahuman being.

Publications and references, including but not limited to patents andpatent applications, cited in this specification are herein incorporatedby reference in their entirety in the entire portion cited as if eachindividual publication or reference were specifically and individuallyindicated to be incorporated by reference herein as being fully setforth. Any patent application to which this application claims priorityis also incorporated by reference herein in the manner described abovefor publications and references.

While this invention has been described with an emphasis upon preferredembodiments, it will be obvious to those of ordinary skill in the artthat variations in the preferred devices and methods may be used andthat it is intended that the invention may be practiced otherwise thanas specifically described herein. Accordingly, this invention includesall modifications encompassed within the spirit and scope of theinvention as defined by the claims that follow.

What is claimed:
 1. A method of treating or ameliorating an indicationof non-mucosal topical tissue that is contact or atopic dermatitis;impetiginized eczema; nummular eczema; endogenous chronic infectiousdermatitis; stasis dermatitis; pyoderma; nuchal eczema; chroniceczematoid otitis externa; localized or disseminated neurodermatitis;lichen simplex chronicus; anogenital pruritus; folliculitis; bacterialdermatoses; mycotic dermatoses; moniliasis; intertrigo; pseudomonasinfections; ecthyma, candidiasis; herpes simplex lesions;dermatophytoses; staphylococcal infections; proctitis; hidradenitissuppurativa; rhinitis; sinusitis; scabies; cutaneous larva migrans;tinea; urinary tract infections; or cutaneous penile lesions, comprisingperiodically applying to such disease affected tissue a compositioncomprising an effective amount of an appropriate composition of herbalextract(s) of one or more of Sambucus nigra, Centella asiatica orEchinacea purpurea, and an effective amount of a quaternary ammoniumsurfactant, wherein the quaternary ammonium surfactant comprises a1-alkylpyridinium salt, where alkyl is C8-C36.
 2. The method of claim 1,further comprising applying to a portion of the tissue a film, patch oran adhesive solid formulation comprising appropriate composition ofherbal extract(s) of one or more of Sambucus nigra, Centella asiatica orEchinacea purpurea.
 3. The method of claim 1, wherein the extract(s) ofone or more of Sambucus nigra, Centella asiatica or Echinacea purpureacomprise an antiinflammatory amount.
 4. The method of claim 1, whereinSambucus nigra extract is more than 50% to 90% by weight of the plantextract solids and Centella asiatica is 1% to less than 50% by weight ofthe plant extract solids, and the surfactant is a 1-alkylpyridiniumsalt, where alkyl is C8-C36, the surfactant present in an amount from0.01 to 5% of the formulation by weight.
 5. The method of claim 4,further comprising applying to a portion of the tissue a film, patch oran adhesive solid formulation comprising appropriate composition ofherbal extract(s) of one or more of Sambucus nigra, Centella asiatica orEchinacea purpurea.
 6. The method of claim 1, wherein the indication ofnon-mucosal topical tissue is contact or atopic dermatitis;impetiginized eczema; nummular eczema; stasis dermatitis; nuchal eczema;localized or disseminated neurodermatitis; lichen simplex chronicus;proctitis; hidradenitis suppurativa; sinusitis; or cutaneous penilelesions.
 7. The method of claim 6, further comprising applying to aportion of the tissue a film, patch or an adhesive solid formulationcomprising appropriate composition of herbal extract(s) of one or moreof Sambucus nigra, Centella asiatica or Echinacea purpurea.
 8. Themethod of claim 6, wherein the extract(s) of one or more of Sambucusnigra, Centella asiatica or Echinacea purpurea comprise anantiinflammatory amount.
 9. The method of claim 6, wherein Sambucusnigra extract is more than 50% to 90% by weight of the plant extractsolids and Centella asiatica is 1% to less than 50% by weight of theplant extract solids, and the surfactant is a 1-alkylpyridinium salt,where alkyl is C8-C36, the surfactant present in an amount from 0.01 to5% of the formulation by weight.
 10. The method of claim 9, furthercomprising applying to a portion of the tissue a film, patch or anadhesive solid formulation comprising appropriate composition of herbalextract(s) of one or more of Sambucus nigra, Centella asiatica orEchinacea purpurea.
 11. The method of claim 1, wherein the indication ofnon-mucosal topical tissue is contact or atopic dermatitis.
 12. Themethod of claim 1, wherein the indication of non-mucosal topical tissueis anogenital pruritus.
 13. The method of claim 1, wherein theindication of non-mucosal topical tissue is herpes simplex lesions. 14.A method of treating or ameliorating a non-mucosal wound comprisingperiodically applying to the wound a composition comprising an effectiveamount of an appropriate composition of herbal extract(s) of one or moreof Sambucus nigra, Centella asiatica or Echinacea purpurea, and aneffective amount of a quaternary ammonium surfactant that comprises a1-alkylpyridinium salt, where alkyl is C8-C36.
 15. The method of claim14, further comprising applying to a portion of the tissue a film, patchor an adhesive solid formulation comprising appropriate composition ofherbal extract(s) of one or more of Sambucus nigra, Centella asiatica orEchinacea purpurea.
 16. The method of claim 14, wherein the extract(s)of one or more of Sambucus nigra, Centella asiatica or Echinaceapurpurea comprise an antiinflammatory amount.
 17. The method of claim14, wherein Sambucus nigra extract is more than 50% to 90% by weight ofthe plant extract solids and Centella asiatica is 1% to less than 50% byweight of the plant extract solids, and the surfactant present in anamount from 0.01 to 5% of the formulation by weight.
 18. The method ofclaim 17, further comprising applying to a portion of the tissue a film,patch or an adhesive solid formulation comprising appropriatecomposition of herbal extract(s) of one or more of Sambucus nigra,Centella asiatica or Echinacea purpurea.